Format

Send to:

Choose Destination
See comment in PubMed Commons below
Tuberculosis (Edinb). 2005 Jan-Mar;85(1-2):7-12.

The tuberculosis vaccine challenge.

Author information

  • 1Laboratory of Mycobacterial Diseases and Cellular Immunology, Center for Biologics Evaluation and Research, Food and Drug Administration, Bldg 29 Rm 503 HFM-431, 29 Lincoln Drive, Bethesda, MD 20892, USA. brennan@cber.fda.gov

Abstract

Although antibiotic treatments for tuberculosis are available, because of re-infection, drug resistance, AIDS, and economic reasons, it is unlikely that we will be able to control the global spread of tuberculosis without an effective vaccine. A number of new candidate vaccines for tuberculosis are under development and some are being evaluated for safety in normal human subjects in clinical trials. Additional vaccine candidates have been shown to be safe and effective when administered prior to infection in animal models. However, in areas of the world where tuberculosis is endemic, up to two thirds of the population are already infected with Mycobacterium tuberculosis, and it is unlikely that a new pre-exposure vaccine would have a substantial impact on disease for decades. In contrast, a vaccine that could be delivered to individuals already infected could reduce the disease burden. At this time, it is unclear whether the new TB vaccines can be safely and effectively used in populations already infected with M. tuberculosis, immunized with BCG vaccine or infected with HIV. This presents a major challenge to pre-clinical testing and clinical evaluation as well as eventual uptake of the new TB vaccines into areas of the world that are most at risk for tuberculosis.

PMID:
15687021
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk